<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818492</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-04</org_study_id>
    <secondary_id>2012-003632-23</secondary_id>
    <nct_id>NCT01818492</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis</brief_title>
  <official_title>A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seventh Framework Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and efficacy of a new drug
      aimed at controlling disease activity in patients diagnosed with primary haemophagocytic
      lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients
      not previously treated with the current standard of care, or can be given to patients who
      have either failed or were unable to tolerate the current standard of care. Administration
      will be on top of a glucocorticosteroid, which is usually part of the current recommended
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>end of treatment</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Time to response</measure>
    <time_frame>any time during the study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Durability of response</measure>
    <time_frame>any time during the study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>end of the study and beyond</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucocorticoid tapering</measure>
    <time_frame>any time during the study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability of NI-0501 in haemophagocytic lymphohistiocytosis</measure>
    <time_frame>up to end of the study</time_frame>
    <description>Vital signs
Physical examination
Recording of adverse events
Routine laboratory assessments</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Primary Haemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>NI-0501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NI-0501</intervention_name>
    <arm_group_label>NI-0501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: male and female

          -  Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis

          -  Primary HLH patients

          -  Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed
             informed consent

        Exclusion Criteria:

          -  Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven
             rheumatic or neoplastic disease.

          -  Body weight &lt; 3 kg.

          -  Patients treated with biologics within a specific timeframe

          -  Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and
             Leishmania infections.

          -  Presence of malignancy.

          -  Concomitant disease or malformation severely affecting the cardiovascular, pulmonary,
             liver or renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristina de Min, MD</last_name>
    <phone>+41 61 201 1322</phone>
    <email>cdemin@novimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Garrington, MD</last_name>
      <phone>720-777-6740</phone>
      <email>timothygarrington@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Garrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Powell, MD</last_name>
      <phone>302-651-5505</phone>
      <email>Jonathan.Powell@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <phone>404-727-8877</phone>
      <email>shanmuganathan.chandrakasan@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara A Degar, MD</last_name>
      <phone>617-632-5186</phone>
      <email>Barbara_Degar@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A Degar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Kasow, MD</last_name>
      <phone>919-962-8733</phone>
      <email>kimberly_kasow@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Kasow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jordan, MD</last_name>
      <phone>513-636-7287</phone>
      <email>Michael.Jordan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Allen, MD, PhD</last_name>
      <phone>832-824-4312</phone>
      <email>ceallen@txch.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Diaz</last_name>
      <phone>1-832-824-1520</phone>
      <email>mldiaz@txch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carl Allen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark N Fluchel, MD</last_name>
      <phone>801-662-4710</phone>
      <email>Mark.Fluchel@imail2.org</email>
    </contact>
    <investigator>
      <last_name>Mark N Fluchel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Rössig, Prof. Dr. Med.</last_name>
      <phone>0049 2518347742</phone>
      <email>rossig@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Rössig, Prof. Dr. Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Sieni, MD</last_name>
      <phone>+39 055-5662</phone>
      <phone_ext>524</phone_ext>
      <email>e.sieni@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Elena Sieni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi, MD</last_name>
      <phone>0039_010_5636</phone>
      <phone_ext>715</phone_ext>
      <email>concettamicalizzi@ospedale-gaslini.ge.it</email>
    </contact>
    <investigator>
      <last_name>Concetta Micalizzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Rizzari, MD</last_name>
      <phone>0039_039_233</phone>
      <phone_ext>3513</phone_ext>
      <email>c.rizzari@hsgerardo.org</email>
    </contact>
    <investigator>
      <last_name>Carmelo Rizzari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MariaCaterina Putti, MD</last_name>
      <phone>0039 049 8213535</phone>
      <email>mariacaterina.putti@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Mariacaterina Putti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>0039 06 68592678</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesaro, MD</last_name>
      <phone>0039 045 812 7874</phone>
      <email>simone.cesaro@aovr.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Simone Cesaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Dapena, MD</last_name>
      <phone>0034 934893093</phone>
    </contact>
    <investigator>
      <last_name>Jose L Dapena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues De Llobregat (Barcelona)</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laia Alsina Manrique de Lara, MD</last_name>
      <phone>0034 932804000</phone>
      <phone_ext>3330</phone_ext>
      <email>lalsina@hsjdbcn.org</email>
    </contact>
    <investigator>
      <last_name>Laia Alsina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Sevilla, MD</last_name>
      <phone>0034 915035938</phone>
      <email>julian.sevilla@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Julian Sevilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Inge Henter, MD</last_name>
      <phone>0046851772484</phone>
    </contact>
    <investigator>
      <last_name>Jan-Inge Henter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital - Department of Haematology</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anupama Rao, MD</last_name>
      <phone>00442074059200</phone>
      <phone_ext>7918</phone_ext>
      <email>Anupama.Rao@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anupama Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emapalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

